Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of T Cell Receptor-Redirected T Cell Infusion For Prevention of Hepatocellular Carcinoma Recurrence in Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma Post Liver Transplantation

Next Previous
Trial Profile

A Phase I Study of T Cell Receptor-Redirected T Cell Infusion For Prevention of Hepatocellular Carcinoma Recurrence in Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma Post Liver Transplantation

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HBV-specific-TCR-redirected-T-cell-therapy-Lion-TCR (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Lion TCR

    • Most Recent Events

    • 27 Jun 2022 Number of treatment arms have been increased from 1 to 2 by the addition of No intervention and TCR-T (at crossover) arm. Study design is changed from single group assignment to sequential. Upper age limit is increased from 65 years to 75 years, thus including elderly patients also.
    • 01 Jun 2018 New trial record
    • 27 May 2018 According to a Lion TCR media release,the company have raised US$ 20 million in its Series A financing round.The proceeds from this fund raising will be primarily used to advance its on-going clinical trials of LioCyx, including this trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top